Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine
Novel controlled release pharmaceutical compositions for oral use containing midodrine and/or its active metabolite desglymidodrine. The novel compositions are designed to release midodrine and/or desglymidodrine after oral intake in a manner which enables absorption to take place in the gastrointestinal tract so that a relatively fast peak plasma concentration of the active metabolite desglymidodrine is obtained followed by a prolonged and relatively constant plasma concentration of desglymidodrine. The novel compositions may be designed for administration once or twice daily, i.e. a therapeutically effective concentration of desglymidodrine is maintained for a period of at least 10-16 hours followed by a wash out period of about 8-12 hours in order to avoid the well-known midodrine related side effect with respect to supine hypertension. The therapeutically effective concentration of desglymidodrine is regarded as a plasma concentration of desglymidodrine of at least about 3 ng/ml. A composition is designed to release midodrine and/or desglymidodrine in at least the following consecutive steps: i) an initial relatively fast release of midodrine and/or desglymidodrine (in order to obtain a relatively fast onset of action), ii) a steady release or a slower release than in step 1 of midodrine and/or desglymidodrine (in order to maintain a plasma concentration of desglymidodrine which is prolonged and relatively constant), iii) a second rise in release of midodrine and/or desglymidodrine (in order to take advantage of absorption from the colon, i.e. such a second rise release is designed to take place when the composition (or the disintegrated parts of the composition) reaches the colon; normally this is regarded to take about 8 hours after oral intake, and iv) a decline in release rate corresponding to that essentially all midodrine and/or desglymidodrine have been released from the composition. Also disclosed is a method for treating orthostatic hypotension and/or urinary incontinence, the method comprising administration to a patient in need thereof of an effective amount of midodrine and/or desglymidodrine in a composition according to the invention.
1. A controlled release pharmaceutical composition for oral use comprising midodrine (ST 1085) or a pharmaceutically acceptable salt thereof and/or its active metabolite desglymidodrine (ST 1059) or a pharmaceutically acceptable salt thereof,
wherein the in vitro release rate of midodrine and/or desglymidodrine has the following course of events
i) a relatively fast first initial release followed by
ii) a steady release or a slower release than in step i) above, which is followed by
iii) a second rise in release rate that takes place 5-10 hours after start of an in vitro dissolution test and, finally,
iv) a decline in release rate
wherein the composition upon administration provides a relatively fast peak plasma concentration of desglymidodrine, and a therapeutically effective plasma concentration of desglymidodrine is maintained for at least about 9 hours.
2. A controlled release pharmaceutical composition according to claim 1 , wherein
the relatively fast peak plasma concentration of desglymidodrine is obtained about 15 minutes-6 hours after oral administration.
3. A composition according to claim 1 , wherein the plasma concentration of desglymidodrine is maintained at a therapeutically active level for about 4.5-14 hours.
4. A composition according to claim 1 , wherein the plasma concentration of desglymidodrine is maintained at a relatively constant level for about 4.5-16 hours.
5. A composition according to claim 4 , wherein the relatively constant level n is ±60%, and wherein n is the plasma concentration in ng/ml and monitored in healthy persons.
6. A composition according to claim 1 containing midodrine or a pharmaceutically acceptable salt thereof.
7. A composition according to claim 6 , wherein the plasma concentration of midodrine after oral administration is maintained at a relatively constant level for about 0.7-4 hours.
8. A composition according to claim 7 , wherein the relatively constant level m is ±60%, and wherein m is the plasma concentration in ng/ml and monitored in healthy persons.
9. A composition according to claim 6 , wherein the release pattern of midodrine from the composition—when tested in vitro using Dissolution Method I or II and employing a basket according to USP and Ph. Eur, 100 rpm, 600 ml 1 N hydrochloric acid as dissolution medium and a temperature of 37° C.—is:
1-15% w/w is released from the composition within the first 30 min after start of the test,
10-35% w/w is released about 30 min after start of the test,
15-40% w/w is released about 1 hour after start of the test,
20-50% w/w is released about 2 hours after start of the test,
20-55% w/w is released about 3 hours after start of the test,
25-75% w/w is released about 4 hours after start of the test,
30-74% w/w is released about 6 hours after start of the test,
40-85% w/w is released about 8 hours after start of the test,
65-100% w/w is released about 10 hours after start of the test, and
90-110% w/w is released about 12 hours after start of the test.
10. A composition according to claim 6 , wherein the release pattern of midodrine from the composition—when tested in vitro using Dissolution Method III or IV described herein and employing a basket according to USP and Ph. Eur, 100 rpm, a first dissolution medium with a pH of about 1.0 for the first 2 hours of the testing followed by a second dissolution medium with a pH of about 6.0 for the next 5.5 hours and finally a third dissolution medium with a pH of about 7.5 until the end of the testing, and a temperature of 37° C.—is:
1-15% w/w is released from the composition within the first 30 min after start of the test,
10-35% w/w is released about 30 min after start of the test,
15-40% w/w is released about 1 hour after start of the test
20-50% w/w is released about 2 hours after start of the test,
20-55% w/w is released about 3 hours after start of the test,
25-75% w/w is released about 4 hours after start of the test,
30-74% w/w is released about 6 hours after start of the test,
40-95% w/w is released about 8 hours after start of the test,
65-100% w/w is released about 10 hours after start of the test, and
75-110% w/w is released about 12 hours after start of the test.
11. A composition according to claim 6 , wherein the release pattern of midodrine from the composition—when tested in vitro employing an in vitro dissolution method is:
1-15% w/w is released from the composition within the first 30 min after start of the test,
10-35% w/w is released about 30 min after start of the test,
15-40% w/w is released about 1 hour after start of the test,
20-50% w/w is released about 2 hours after start of the test,
20-55% w/w is released about 3 hours after start of the test,
25-75% w/w is released about 4 hours after start of the test,
30-74% w/w is released about 6 hours after start of the test,
35-85% w/w is released about 7 hours after start of the test,
45-95% w/w is released about 8 hours after start of the test,
65-100% w/w is released about 10 hours after start of the test, and
90-110% w/w is released about 12 hours after start of the test.
12. A composition according to claim 6 , wherein the release pattern of midodrine from the composition—when tested in vitro employing an in vitro dissolution method is as follows (±30% w/w of the values stated below):
about 25% w/w is released about 30 min after start of the test,
about 35% w/w is released about 1 hour after start of the test,
about 39% w/w is released about 2 hours after start of the test,
about 47% w/w is released about 3 hours after start of the test,
about 53% w/w is released about 4 hours after start of the test,
about 66 w/w is released about 6 hours after start of the test,
about 75% w/w is released about 7 hours after start of the test,
about 80% w/w is released about 8 hours after start of the test, and
about 90% w/w is released about 10 hours after start of the test, and
about 100% w/w is released about 12 hours after start of the test.
13. A composition according to claim 1 , wherein the steady release period ii) starts about 1-3 hours after start of the test.
14. A composition according to claim 1 or 13 , wherein the steady release period ii) is maintained for at least 2 hours.
15. The composition according to claim 1 , wherein the second rise in release rate takes place 5-10 hours after start of the in vitro release.
16. A composition according to claim 1 , wherein the release pattern of midodrine and/or desglymidodrine from the composition—when tested in vitro employing any Dissolution Method as described herein,—is as follows (±30% w/w of the values stated below):
about 25% w/w is released about 30 min after start of the test,
about 35% w/w is released about 1 hour after start of the test,
about 39% w/w is released about 2 hours after start of the test,
about 47% w/w is released about 3 hours after start of the test,
about 53-56% w/w is released about 4 hours after start of the test,
about 66-72% w/w is released about 6 hours after start of the test,
about 80-85% w/w is released about 8 hours after start of the test,
about 93% w/w is released about 10 hours after start of the test, and
about 100% w/w is released about 12 hours after start of the test.
17. A composition according to claim 1 , wherein the release pattern of midodrine and/or desglymidodrine from the composition—when tested in vitro employing any Dissolution Method as described herein—is as follows (±30% w/w of the values stated below):
about 28% w/w is released about 30 minutes after start of the test,
about 35% w/w is released about 1 hour after start of the test,
about 41% w/w is released about 2 hours after start of the test,
about 45% w/w is released about 3 hours after start of the test,
about 55% w/w is released about 4 hours after start of the test,
about 70 w/w is released about 6 hours after start of the test,
about 78% w/w is released about 7 hours after start of the test, and
about 90% w/w is released about 8 hours after start of the test,
about 95% w/w is released about 10 hours after start of the test, and
about 100% w/w is released about 12 hours after start of the test.
18. A controlled release pharmaceutical composition for oral use comprising midodrine (ST 1085) or a pharmaceutically acceptable salt thereof and/or its active metabolite desglymidodrine (ST 1059) or a pharmaceutically acceptable salt thereof,
wherein the in vitro release rate of midodrine and/or desglymidodrine has the following course of events
i) a relatively fast first initial release followed by
ii) a steady release or a slower release than in step i) above, which is followed by
iii) a second rise in release rate that takes place 5-10 hours after start of an in vitro test and, finally,
iv) a decline in release rate
and wherein the release pattern of midodrine and/or desglymidodrine from the composition—when tested in vitro employing an in vitro dissolution Method as described herein,—is as follows (±30% w/w of the values stated below):
about 25% w/w is released about 30 min after start of the test,
about 35% w/w is released about 1 hour after start of the test,
about 39% w/w is released about 2 hours after start of the test,
about 47% w/w is released about 3 hours after start of the test,
about 53-56% w/w is released about 4 hours after start of the test,
about 66-72% w/w is released about 6 hours after start of the test,
about 80-85% w/w is released about 8 hours after start of the test,
about 93% w/w is released about 10 hours after start of the test, and
about 100% w/w is released about 12 hours after start of the test.
19. A controlled release pharmaceutical composition for oral use comprising midodrine (ST 1085) or a pharmaceutically acceptable salt thereof and/or its active metabolite desglymidodrine (ST 1059) or a pharmaceutically acceptable salt thereof,
wherein the in vitro release rate of midodrine and/or desglymidodrine has the following course of events
i) a relatively fast first initial release followed by
ii) a steady release or a slower release than in step i) above, which is followed by
iii) a second rise in release rate that takes place 5-10 hours after start of an in vitro test and, finally,
iv) a decline in release rate
and wherein the release pattern of midodrine and/or desglymidodrine from the composition—when tested in vitro employing an in vitro dissolution method as described herein—is as follows (±30% w/w of the values stated below):
about 28% w/w is released about 30 min after start of the test,
about 35% w/w is released about 1 hour after start of the test,
about 41% w/w is released about 2 hours after start of the test,
about 45% w/w is released about 3 hours after start of the test,
about 55% w/w is released about 4 hours after start of the test,
about 70 w/w is released about 6 hours after start of the test,
about 78% w/w is released about 7 hours after start of the test,
about 90% w/w is released about 8 hours after start of the test,
about 95% w/w is released about 10 hours after start of the test, and
about 100% w/w is released about 12 hours after start of the test.
20. A composition according to claim 18 or 19 , wherein the composition upon administration results in a relatively fast peak plasma concentration of desglymidodrine, and a therapeutically effective plasma concentration of desglymidodrine is maintained for at least about 9 hours.
21. A composition according to claim 20 , wherein the steady release period ii) starts about 1-3 hours after start of the test.
22. A composition according to claim 20 , wherein the steady release period ii) is maintained for at least 2 hours.
23. A method for treating a patient suffering from syncope, the method comprising administering an effective amount of midodrine and/or desglymidodrine in the form of a controlled release composition according to claim 1 to a patient in need thereof.
24. A method for treating a patient suffering from orthostatic hypotension and/or urinary incontinence, the method comprising administering an effective amount of midodrine and/or desglymidodrine in the form of a controlled release composition according to claim 1 to a patient in need thereof.
25. A method of claim 24 , wherein the patient is suffering from orthostatic hypotension.
26. A method of claim 24 , wherein the patient is suffering from urinary incontinence.
27. A method of claim 24 , wherein the patient is suffering from urinary stress incontinence.